Riglitazone is a new generation of hypoglycemic drug, which has less effect on liver and kidney function, but long-term use of Riglitazone needs to pay attention to hypoglycemic reaction, angioedema and other possibilities. Riglitazone is a dipeptidyl peptidase inhibitor hypoglycemic drug, mainly used in type 2 diabetes mellitus blood glucose control, can be used alone or combined with metformin or sulfonylurea together. Riglitazide does not require dosage adjustment in patients with hepatic or renal insufficiency, but regular monitoring of hepatic and renal function is required, and may cause transient elevation of liver enzymes. Similar to other hypoglycemic drugs, long-term use of Riglitazone requires regular monitoring of blood glucose to avoid symptoms of hypoglycemia; a small number of patients may experience angioedema, urticaria, diarrhea and other adverse reactions during the use of the drug. Patients who are allergic to this product are prohibited; pregnant women, lactating women with caution; for patients with type 1 diabetes mellitus or diabetic ketoacidosis should not be used. If discomfort occurs during the medication, it is recommended to go to the hospital in a timely manner so that the doctor can guide the adjustment of medication.